Coronavirus: EMA to submit Merck's anti-Covid drug to an ongoing review
Eva Deschamps / October 26, 2021
The European Medicines Agency EMA will submit the anti-Covid drug from U.S. pharmaceutical companies Merck and Ridgeback Bio to a continuing review, it announced Monday.
If the pill, called molnupiravir, gets the green light, it would be the first oral coronavirus drug to be approved.
The rolling review process allows the EMA to evaluate safety and efficacy data as they come in. Therefore, there is no need to wait for a formal application from the producer. The objective is to speed up the evaluation of an application if it is actually submitted.
The two companies themselves announced the results of the Phase 3 study earlier this month. The study appears to show that the treatment reduced the risk of hospitalization or death in the event of infection by half.
Related Posts
Coronavirus: Biden administration withdraws mandatory vaccination in large companies
Steph Deschamps / January 26, 2022
President Joe Biden's administration on Tuesday formally withdrew the vaccinatio...
Read More
Public humiliation in China: accused of violating anti-Covid measures, they are forced to march in handcuffs in the streets.
Sylvie Claire / December 30, 2021
Four people accused of violating anti-Covid rules were forced to parade in the sou...
Read More
New Zealander gets 10 Covid shots in ONE day: investigation launched
Steph Deschamps / December 11, 2021
New Zealand health authorities have launched an investigation after a man got th...
Read More